Avidity Biosciences + Novartis
closed$RNA acquired by Novartis for $12.0B
Deal Summary
Deal Value
$12.0B
Price/Share
$72
Announced
Oct 26, 2025
Closed
Feb 27, 2026
Fund Positioning
10 of 20 tracked specialist biotech funds held $RNA — based on SEC 13F filings.
| Fund | Shares | Value | Entry | At Announcement |
|---|---|---|---|---|
| RA Capital Management | 8.6M | $623.3M | Mar 2025 | Yes |
| RTW Investments | 11.4M | $495.5M | Mar 2025 | Yes |
| Avoro Capital Advisors | 5.5M | $393.5M | Mar 2025 | Yes |
| Casdin Capital | 1.0M | $72.1M | Mar 2025 | Yes |
| Tang Capital Management | 900K | $64.9M | Dec 2025 | No |
| OrbiMed Advisors | 620K | $44.7M | Mar 2025 | Yes |
| Eventide Asset Management | 525K | $37.8M | Mar 2025 | Yes |
| EcoR1 Capital | 765K | $33.3M | Mar 2025 | Yes |
| Baker Bros. Advisors | 625K | $27.2M | Sep 2025 | Yes |
| Driehaus Capital | 45K | $3.3M | Mar 2025 | Yes |